GlaxoSmithKline Pharmaceuticals has informed that a meeting of the Board of Directors of the Company was held today, i.e. 13th May 2025 and transacted the following business: Pursuant to Regulation 33 of LODR the following documents are enclosed- Approved Audited Financial Statements & Results (Standalone and Consolidated) for the quarter & year ended 31st March 2025; Auditors Report for the year ended 31st March 2025; Statement of Assets and Liabilities; Certificate for unmodified opinion The Board has recommended a final dividend of Rs 42 per equity share on face value of Rs 10 each for the year ended 31st March 2025, subject to approval of members at 100th Annual General Meeting.
The above information is a part of company’s filings submitted to BSE.
